share_log

George N. Mattson Buys 100,000 Shares of Xos, Inc. (NASDAQ:XOSWW) Stock

George N. Mattson Buys 100,000 Shares of Xos, Inc. (NASDAQ:XOSWW) Stock

喬治 ·N. Mattson 購買 Xos, Inc.(納斯達克股票代碼:XOSWW)10萬股股票
Defense World ·  2023/04/14 17:24

Xos, Inc. (NASDAQ:XOSWW – Get Rating) Director George N. Mattson purchased 100,000 shares of the company's stock in a transaction dated Monday, April 10th. The shares were acquired at an average cost of $0.62 per share, for a total transaction of $62,000.00. Following the transaction, the director now owns 836,039 shares of the company's stock, valued at $518,344.18. The purchase was disclosed in a document filed with the SEC, which is available through this hyperlink.

Xos, Inc.(納斯達克股票代碼:XOSWW — 獲取評級)董事喬治·N·馬特森在4月10日星期一的交易中購買了該公司10萬股股票。這些股票的收購平均成本爲每股0.62美元,總交易額爲62,000.00美元。交易完成後,該董事現在擁有該公司836,039股股票,價值518,344.18美元。此次收購是在向美國證券交易委員會提交的一份文件中披露的,該文件可通過以下方式獲得 這個超鏈接

XOS Stock Performance

XOS 股票表現

NASDAQ:XOSWW opened at $0.04 on Friday. Xos, Inc. has a twelve month low of $0.03 and a twelve month high of $0.44. The business's 50 day moving average is $0.07.

納斯達克股票代碼:XOSWW週五開盤價爲0.04美元。Xos, Inc. 創下十二個月低點0.03美元,十二個月高點爲0.44美元。該公司的50天移動平均線爲0.07美元。

Read More

閱讀更多

  • Get a free copy of the StockNews.com research report on XOS (XOSWW)
  • Delta Airlines Is Ready To Fly Higher
  • Global Payments Climbs After Goldman Sachs Upgrade
  • Fastenal Is At A Critical Turning Point
  • 3 Healthcare Stocks Insiders Are Buying
  • Novo Nordisk Charges Higher and Could be Just Getting Started
  • 免費獲取 StockNews.com 關於 XOS 的研究報告 (XOSWW) 的副本
  • 達美航空已準備好飛得更高
  • 高盛升級後,全球支付攀升
  • Fastenal 正處於關鍵的轉折點
  • 內部人士正在買入 3 只醫療保健股
  • Novo Nordisk 收費更高可能才剛剛起步

Receive News & Ratings for XOS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XOS and related companies with MarketBeat.com's FREE daily email newsletter.

每天接收 XOS 的新聞和評級 -在下面輸入您的電子郵件地址,即可通過Marketbeat.com的免費每日電子郵件時事通訊接收XOS及相關公司的最新新聞和分析師評級的簡明每日摘要。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論